Item 8.01. Other Events.

On January 27, 2021, BeiGene, Ltd. ("BeiGene") announced that the global Phase 3 RATIONALE 302 trial of its anti-PD-1 antibody tislelizumab versus investigator's choice chemotherapy in patients with advanced unresectable or metastatic esophageal squamous cell carcinoma (ESCC) who have received prior systemic treatment met its primary endpoint of overall survival (OS). In the trial results, tislelizumab demonstrated a statistically significant and clinically meaningful improvement in OS in the intention-to-treat (ITT) population, when compared to chemotherapy. The safety profile of tislelizumab was consistent with its known risks, with no new safety signals identified. The full text of this press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.



(d) Exhibits.
   Exhibit No.           Description

       99.1              Press Release titled "BeiGene Announces Positive Topline Results for Global
                         Phase 3 Trial of Tislelizumab in Esophageal Squamous Cell Carcinoma" issued
                         on January 27, 2021.

       104               The cover page from this Current Report on Form 8-K, formatted in Inline
                         XBRL.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses